CAR-T Therapies for Aggressive Large Cell Lymphoma Age ≥ 18 Yrs

CAR Therapies following prior CAR Therapy

Expanded Access protocols for commercial CAR-T products manufactured of specification

CCT5045
EAP for Patients Receiving Liso-CTC
Maraleucel That is Not conforming for Commercial Release
Pt: Miklos Sponsor: Novartis

CCT5028
Phase II Liso-CTC in 2nd-Line Therapy in Adult Aggressive B-cell NHL
Pt: Gupta Sponsor: Juno Therapeutics

2nd line CAR Therapies

3rd line CAR Therapies

Age < 65 Yrs

Age > 65 Yrs

CCT5029
Phase I/ib Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies
Pt: Muffy Stanford

CCT5024
Phase III ALLO-501 (AntiCD19 Allogeneic CAR TCell Tx) Relapsed/Refractory Large B-Cell & Follicular Lymphoma
Pt: Miklos Alligone

CCT5025
Phase 1/2a PBCAR20A in Relapsed/Refractory (R/R) NHL or R/R CLL or Small Lymphocytic Lymphoma
Pt: Miklos Sponsor: Pending

CCT5006
Expanded Access Axicabtagene Ciloleucel in Tx Relapsed/Refractory T-plant, Ineligible Aggressive NHL
Pt: Miklos Sponsor: Kite

CCT5016
Managed Access Program (MAP) CTL019 in ALL or DLBCL
Pt: Miklos Sponsor: Novartis

CCT5044
Phase II trial of Bi-cistronic sCD19 & α-20 CD22 CAR-T
Pt: Miklos Sponsor: Pending

CCT5018
Phase II Axicabtagene Ciloleucel in Combo w/ Utomilamab in Refractory Large B-Cell Lymphoma
Pt: Parveen Sponsor: Kite Pharma

CCT5036
Phase I/Ill Lenzaalumab &Axicabtagene Ciloleucel in Relapsed /Refractory Large B-cell Lymphoma
Pt: Parveen Sponsor: Novartis

CCT5032
Phase II Lenzaalumab &Axicabtagene Ciloleucel in Relapsed/Refractory Large B-Cell Lymphoma
Pt: Parveen Sponsor: Kite Pharma

CCT5020
Phase I/II Anti-CD20 &Anti-CD19 Specific Chimeric Antigen Receptor in Relapsed and/or Refractory DLBCL
Pt: Miklos Sponsor: Pending

CCT5042
Phase II Anti-CD20 &Anti-CD19 Specific Chimeric Antigen Receptor in Relapsed and/or Refractory DLBCL
Pt: Miklos Sponsor: Pending